{"name":"Theriva Biologics, Inc.","slug":"theriva-biologics-inc","ticker":"","exchange":"","domain":"therivabiologics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":8604000,"netIncome":-18349000,"cash":13056000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2011"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE84Mi1tY0d3aUZuZXVDdmhJZGZLWVhwUmRZUy0xZVRFeTE5QlNtcUFjaFR4YTRHRk9XeVAySzB2ZnBjVVZKNkVuczh2OUY2dnNWamE1Vzk5bmZlRkZiT2g0c0haOEduSEpMNmdXY1dn?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan","headline":"If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX)","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPZzB2OC1WY0FJcm0wTlpDUUhGOFBwN0IxMHR4cWZ6NVd0d045SUxuQUQ5NW1WVC1OeldiNTlBMEhUcFhja1ZianN1aU5SSklMT3o1ZEttc0trTHVVa2FwbmZFN0NNRHpHdFpuOTdBTjh5d25EWDlDX1ZuMmFyZnBCc3dxbEJOR3VCZHVBdjh0aTFWMFFRUDVReDFPNWlGY2pscllxY3lHVUlCVUZCSnlVaS1oV1R2QzFEVDRSU0R4WUxnaE5MSExpTQ?oc=5","date":"2026-02-19","type":"deal","source":"The Pharma Letter","summary":"Theriva Biologics licenses SYN-020 to Rasayana Therapeutics for multiple indications - The Pharma Letter","headline":"Theriva Biologics licenses SYN-020 to Rasayana Therapeutics for multiple indications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQOWxEM0sxM0ltZjRBQlhLZ0ppUXFLaU4xMmVTaWVXOEV1T0MzelY0UzB0TllSeTI0NVE1OTJPNzZxOUZIRnB6cV95T3gyVEtwY0VuQ2ZqQ2lRZ1haREFWR2JyTHpxWDFmNzl5X29jVEI1Y25XZnZpNXE4anFaX3VaMHVuNWkzQWpVQkt4UWVRLTVUQ2twb0VfSWRwRWsxS2NJWlQxN0gtWEo0ZHV4R2pfN2l4RVlLMS0xVHdNODMwZ094YU9Ob1FNRmlrMjFtMTFDMzRWRVBqUUNDZw?oc=5","date":"2026-02-19","type":"regulatory","source":"Benzinga","summary":"Why Etsy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Etsy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPYjg2Z1otR1FWaTZlQy1Kd0ZqTk1xSHJFTnFfNHA2M3ptZWptNW94QjQ1UnJGZVFrdjhtRDRNT0JFQ0c3SGVaSTg4bzNYbTRtb29FdVV3MU5Fa2dmWjl0dVFETGduWkpBS0tDZ19vaE8zOGlCTVBPSVgyZ1hMQXdsakRMcjhvZWhadFZSMmFRS1c0M2thWTNsc2xaWEpYb2l3SFdqOEdiRXZQUVRLaGdTU2FXZm9mR244cndrcHVxb1pBcmc5T1R5OTc1R0N4eFU3MC1OME4xWUdHZ0QtdGlyamRsSnpLbUpkWUJKZ0pocDk?oc=5","date":"2025-10-23","type":"pipeline","source":"InvestorNews","summary":"Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion - InvestorNews","headline":"Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNSks3ZFE3Y01OeFAzeGoxbDdvVW9SVm9vamtZTEc1UGlHdzNVMEt6WWF0UkJxclYzYnFRcVF4N0tqZDZmTnpIMEhEX3YxLUt0dkQyeTdBWXFPb1hTZ19UTFZkSEl5UU5iMXJGc0Y4ZEFEckNnNk02cjBhZXpDV01qY0w2eFpHV1BWTXYwTE9Id2dSTVZ4NEdPTmFIRldLV3l6ZkdRUG5pb3dLT01yZDljQlF0UEszdEhIa0dHNVJfdkx1THh5?oc=5","date":"2025-10-16","type":"earnings","source":"Benzinga","summary":"Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings - Benzinga","headline":"Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE96SGhiTllQQ2IxdVRzNWJkSG12UW1kUHBjUzNwZjJkSTlXNXJqY1NHVS1HV3ZLV3Zxc042N3BVZjZNUGg2RTdDTzVkam83UWdma01BMQ?oc=5","date":"2025-06-03","type":"deal","source":"Intellectia AI","summary":"TOVX Forecast — Price Prediction for 2026. Should I Buy TOVX? - Intellectia AI","headline":"TOVX Forecast — Price Prediction for 2026. Should I Buy TOVX?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2011-12-31","revenueHistory":[{"value":0,"period":"2011-12-31"},{"value":2614000,"period":"2010-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8604000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-18349000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":13056000,"cashHistory":[],"totalAssets":38239000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}